United Therapeutics's revenue for the
three
months ended in Dec. 2023 was $615 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $2,328 Mil.
United Therapeutics's Revenue per Share for the
three
months ended in Dec. 2023 was $12.29.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $46.83.
During the past 12 months, the average Revenue per Share Growth Rate of United Therapeutics was 17.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 12.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 5.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 6.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, United Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 260.90% per year. The lowest was -4.70% per year. And the median was 26.70% per year.
United Therapeutics Revenue Historical Data
The historical data trend for United Therapeutics's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
United Therapeutics Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Revenue
1,448.80
1,483.30
1,685.50
1,936.30
2,327.50
United Therapeutics Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Revenue
491.50
506.90
596.50
609.40
614.70
Competitive Comparison
For the Biotechnology subindustry, United Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics Revenue Distribution
For the Biotechnology industry and Healthcare sector, United Therapeutics's Revenue distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Revenue falls into.
United Therapeutics Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,328 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (NAS:UTHR) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
United Therapeutics Revenue Related Terms
Thank you for viewing the detailed overview of United Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
United Therapeutics (United Therapeutics) Business Description
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
UTHR has been successfully added to your 